Journal of Neurology

, Volume 262, Issue 4, pp 1024–1034 | Cite as

Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study

  • Emmanuelle Le Page
  • Véronique Deburghgraeve
  • Marie-Antoinette Lester
  • Isabelle Cardiet
  • Emmanuelle Leray
  • Gilles Edan
Original Communication

Abstract

Our study aimed to describe safety and neurological impact of alemtuzumab as last-line rescue therapy in aggressive multiple sclerosis (MS) patients, previously treated by Mitoxantrone (MITOX). Between June 2004 and October 2013, 13 patients received alemtuzumab at 20 mg/day and 3 at 12 mg/day for 5 days. EDSS, relapses, secondary progression were prospectively assessed 12 and 6 months before treatment, at baseline and every 3 months. Mean follow-up was 6.2 years [1–10]. Mean age at alemtuzumab start was 40 years [26–49] for 8 Secondary Progressive (SP) and 30 years [26–35] for 8 Relapsing-Remitting (RR) patients. MS duration was 13.7 (±3) and 8.3 (±4) years, respectively. During the 12 months before alemtuzumab, annual relapse rate was 0.75 and 3.14, respectively and the 16 patients accumulated 2–30 new gadolinium enhancing lesions. 4 patients (suboptimal responders) received alemtuzumab during MITOX and 12 patients 1–7.8 years after MITOX. Out of 8 SPMS, 2 were disease free up to last visit (4.7 and 8 years), 5 improved or stabilized but only transiently and 1 worsened. Out of 8 RRMS, 1 remained stable up to last visit (8.7 years) despite 1 relapse and active MRI at 18 months and 7 improved (1–4 point EDSS): 4 remained disease free up to last visit (12, 24, 38 months and 7 years), 2 were successfully retreated at 25 and 33 months and 1 worsened progressively 24 months after alemtuzumab. 2 patients developed Grave’s disease and 1 hypothyroidism. Alemtuzumab controls aggressive RRMS despite previous use of MITOX.

Keywords

Aggressive multiples sclerosis Mitoxantrone Alemtuzumab Rescue therapy 

Notes

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical standard

Alemtuzumab was approved by the US Food and Drug administration (FDA: as CAMPATH) and the European Medicine Evaluation Agency (EMEA: as MABCAMPATH) in hematologic malignancies in May and July 2001, respectively. The present study was approved by the local committee COMEDIMS (Comité du Médicament et Dispositifs Médicaux-Sanitaires) in the University Hospital Pontchaillou, Rennes, France, promoting this study. The EDMUS database received approval from the French “Comission Nationale Informatique et Liberté”.

References

  1. 1.
    The CAMMS223 Trial Investigators (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786–1801. doi:10.1056/NEJMoa0802670 CrossRefGoogle Scholar
  2. 2.
    Cohen JA, Coles AJ, Arnold DL et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 380:1819–1828CrossRefPubMedGoogle Scholar
  3. 3.
    Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized phase 3 trial. Lancet 380:1829–1839CrossRefPubMedGoogle Scholar
  4. 4.
    Coles AJ, Wing M, Molyneux P et al (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296–304CrossRefPubMedGoogle Scholar
  5. 5.
    Moreau T, Thorpe J, Miller D et al (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344:298–301CrossRefPubMedGoogle Scholar
  6. 6.
    Coles AJ, Cox A, Le Page E et al (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98–108CrossRefPubMedGoogle Scholar
  7. 7.
    Esposito F, Radaelli M, Martinelli V et al (2010) Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 16:1490–1499CrossRefPubMedGoogle Scholar
  8. 8.
    Edan G, Miller D, Clanet M et al (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Le Page E, Leray E, Taurin G et al (2008) Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 79:52–56CrossRefPubMedGoogle Scholar
  10. 10.
    Edan G, Comi C, Le Page E et al (2011) Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 82:1344–1350CrossRefPubMedGoogle Scholar
  11. 11.
    Leray E, Yaouanq J, Le Page E et al (2010) Evidence of a two stage disability progression in multiple sclerosis. Brain 133:1900–1913PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Emmanuelle Le Page
    • 1
  • Véronique Deburghgraeve
    • 1
  • Marie-Antoinette Lester
    • 2
  • Isabelle Cardiet
    • 2
  • Emmanuelle Leray
    • 3
  • Gilles Edan
    • 1
  1. 1.Departement of NeurosciencesUniversity Hospital PontchaillouRennes CedexFrance
  2. 2.Departement of PharmacologyUniversity Hospital PontchaillouRennes CedexFrance
  3. 3.Biostatistics DepartmentEHESPRennesFrance

Personalised recommendations